Clinical Trials Logo

Filter by:
NCT ID: NCT00808613 Withdrawn - Arthropathy of Knee Clinical Trials

Optetrak Posterior Stabilized Versus Optetrak Hi-Flex

Start date: December 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the differences in clinical outcomes between the Optetrak® Posterior Stabilized ("Optetrak® PS", Exactech, Gainesville, FL) and the Optetrak® Hi-Flex™ ("Optetrak® HF", Exactech, Gainesville, FL) knee designs.

NCT ID: NCT00808145 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)

Start date: February 2009
Phase: Phase 2
Study type: Interventional

This study will look at the safety and efficacy of treating advanced hepatocellular carcinoma in patients who have not yet received systemic chemotherapy. Previous local treatment of hepatic lesions is permitted The treatment will use a combination of three FDA approved chemotherapy drugs, Gemcitabine, Cisplatin and Sorafenib. Sorafenib is FDA approved for the treatment of hepatocellular cancer, gemcitabine and cisplatin are not approved for the treatment of hepatocellular cancer.

NCT ID: NCT00805610 Withdrawn - Liver Failure Clinical Trials

Hepatocyte Transplantation in Liver Failure

Start date: June 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators research will examine the safety and efficacy of hepatocyte transplantation in the patient with acute liver failure without history of chronic disease. The investigators will study the effectiveness in providing a bridge of support for patient survival until whole organ transplantation is possible. This support may also be a bridge to recovery; by allowing the native liver to recover so that orthotopic liver transplant is not necessary. The investigators will also study the safety and efficacy of hepatocyte transplantation in the patient with chronic liver disease. Underlying etiologies of chronic disease may arise from cirrhosis, fibrosis or inherited metabolic disorders. The investigators will examine cell transplantation in end-stage patients not eligible for whole organ transplant. These patients may benefit with an amelioration of symptoms that will allow other therapeutic treatments. The investigators study will also examine the ability of transplanted hepatocytes to treat inherited metabolic diseases (ex., Crigler-Najjar Disease, Familial Hypercholesterolemia, Urea Cycle Disorders). Cell transplant may also act as a 'bridge' to whole organ transplant or improve function, permitting easier disease control through traditional therapy.

NCT ID: NCT00804960 Withdrawn - Infertility Clinical Trials

Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?

Cost-Less
Start date: September 2008
Phase: Phase 4
Study type: Interventional

This research is being done to determine whether the success rate of in vitro fertilization treatment can be improved, while lowering the cost incurred from infertility medications using a pill called letrozole.

NCT ID: NCT00804882 Withdrawn - Heart Failure Clinical Trials

Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure

CHAMP-HF
Start date: October 2008
Phase: N/A
Study type: Observational

The investigators aim to examine how medical conditions that indicate high cardiometabolic risk, such as increased body weight, high cholesterol levels and high blood pressure, affect heart structure and function among individuals with known HF. Furthermore, this study is being undertaken to identify potential differences in these effects between non-Hispanics whites and Mexican Americans.

NCT ID: NCT00804180 Withdrawn - Anxiety Clinical Trials

Group Therapy Intervention for Children and Adolescents With Injection-Related Anxiety and Their Caregivers

Start date: October 2008
Phase: N/A
Study type: Interventional

The specific aim of this project is to determine the impact of this group therapy intervention on improving adherence, coping, and functioning among children and adolescents with disease processes requiring injections who experience injection-related anxiety.Hypotheses include: 1. General psychosocial (quality of life) improvements from beginning to post-treatment as well as maintenance of these improvements 2-4 weeks following the termination of treatment for both youth and parents. 2. Reduced injection-related anxiety from baseline to post-treatment as well as maintenance of this improvement 2-4 weeks following the end of treatment for both youth and parents. 3. Reduced anxiety immediately following exposure to feared injection- related stimuli. 4. For participants experiencing poor adherence to medical treatment, improvement in adherence as reported by both parents and youth from baseline to post-treatment as well as maintenance of these improvements 2-4 weeks following the end of treatment.

NCT ID: NCT00803478 Withdrawn - Myopia Clinical Trials

The Effect of Hinge Position and Hinge Width on Corneal Sensation and Dry Eye After IntraLase LASIK Procedure

IDES
Start date: June 2004
Phase: N/A
Study type: Interventional

Corneal sensation is known to play a role in tear secretion. Decreased sensation leads to decreased tear production; and when bilateral, leads to a decreased blink rate as well. Dry eyes are a common side effect of LASIK. Incidence rates vary widely, but have been reported in as many as 59% of patients. And almost all patients have some transient dry eye symptoms immediately following LASIK. Previous studies have looked at the effect of hinge position (superior vs. nasal) and hinge width on corneal sensation and dry eye after LASIK performed with a mechanical microkeratome. Corneal sensation was decreased and dry eye signs and symptoms increased immediately following LASIK in all eyes. These parameters then improved at all time periods between 1 week and 6 months post-operative. Loss of corneal sensation and dry eye signs and symptoms were greater in eyes with superior-hinge flap than nasal-hinge flap, and in eyes with narrower hinge flap rather than wider hinge flap IntraLase LASIK, using the IntraLase femtosecond laser rather than a mechanical microkeratome to cut the corneal flap, has become an increasingly popular procedure. It provides several advantages over mechanical microkeratomes, including reduced surgical complications, more predictable flap thickness, better astigmatic neutrality, decreased epithelial injury, and an ability to operate on a wider range of patients. The investigators propose this study to evaluate the effect of flap hinge size and flap thickness in corneal flaps created with the IntraLase laser. The investigators would like to determine if there is a difference from the previously discussed results found when using the mechanical microkeratome. Also, with the increased ease of programming alternate hinge width or flap thickness with IntraLase, if the investigators find a significant difference with an alternate flap configuration, it might translate to a feasible change in clinical practice.

NCT ID: NCT00803374 Withdrawn - Melanoma Clinical Trials

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Start date: November 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable

NCT ID: NCT00802646 Withdrawn - Vaginal Delivery Clinical Trials

The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers

CSE
Start date: June 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the epidural of local anesthetics has an effect on fever that may occur in first time mothers during labor.

NCT ID: NCT00801918 Withdrawn - Clinical trials for Anaplastic Large-Cell Lymphoma

Denileukine Diftitox for Relapsed ALCL

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine is Denileukin diftitox will be safe, well tolerated and induce a significant overall response alone and in combination with chemotherapy: ifosfamide, carboplatin and etoposide (ICE) and will be safe and well tolerated in a population of children, adolescents and young adults with relapsed or refractory anaplastic large cell lymphoma (ALCL).